Shares of Bristol-Myers Squibb Co. rose by about 1% on Monday afternoon following an upgrade from Jefferies. The brokerage upgraded the stock to ‘Buy’ from ‘Hold’ and raised its price target to $70, ...

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...

MapLight Therapeutics was assigned a Hold rating ahead of its Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia expected in mid-August. ML-007C-MA is positioned as a best-in-class challenger to ...

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher ...

MapLight Therapeutics said on Monday its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of ​a mid-stage trial, sending its shares tumbling ...